Munich Precision Oncology is establishing specialized precision oncology centers worldwide, utilizing advanced theranostic technologies to deliver personalized cancer treatment. These centers aim to enhance patient outcomes by integrating genomic profiling and targeted therapies, addressing the need for tailored oncological care.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatment approaches often lack personalization, leading to suboptimal outcomes and increased side effects. Traditional methods may not effectively target individual tumor characteristics, resulting in limited efficacy and potential harm to healthy tissues. The absence of precise diagnostic and therapeutic integration hinders the ability to tailor treatments based on specific patient biomarkers.
Solution
Munich Precision Oncology (MPO) is developing specialized theranostic centers that leverage advanced technologies to deliver personalized cancer treatment. These centers integrate diagnostic imaging with targeted therapies, enabling treatments based on individual biomarkers. By combining medical, scientific, and technical expertise with advanced infrastructure, MPO aims to improve patient outcomes through precision medicine. The centers will utilize radiomolecular precision oncology, merging therapy and diagnostics to enhance treatment precision and minimize side effects.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options, as well as oncologists and medical professionals looking to integrate advanced theranostic technologies into their practice.
Features
- Integration of diagnostic imaging and targeted therapies for personalized treatment plans
- Use of radioisotopes for targeted imaging and delivery of radiation to tumors
- Advanced AI-based data analytics for enhanced diagnostics and treatment planning
- Total body PET/CT scanner for comprehensive imaging
- Focus on radiomolecular theranostics, combining therapy and diagnostics